Health
Commonly-prescribed drug for IBD blunts COVID-19 vaccine response – News-Medical.Net
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after…
People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.
The research measured antibody responses after vaccination with the Pfizer/BioNTech or the Oxford/AstraZeneca COVID-19 vaccine in 865 people treated with infliximab, an anti-tumour necrosis factor (anti-TNF) biologic drug, prescribed to around two million people worldwide. Anti-TNF…
-
Noosa News22 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General23 hours agoMinjee Lee rallies after third-round meltdown to share fifth place at LA Championship
-
General16 hours agoUkraine says Russia has ramped up attacks despite ‘Easter truce’
-
General19 hours agoReason v magical climate thinking – voters have no choice